Although the overexpression of FTO are found in several AML subtypes, and it has been reported that MLL fusions may upregulate the expression of FTO by directly targeting it in MLL-rearranged AML cells [18], the underlying molecular mechanism driving FTO overexpression in t(8;21) AML remains to be determined. This evidence concerns the gene KMT2A and acute myeloid leukemia.